知名投行高盛最新发布研究报告，对爱尔兰生物制药公司阿尔克梅斯（ALKS）予以"买入"初始评级。该报告认为，阿尔克梅斯在神经系统疾病治疗领域的产品管线具有显著临床价值，其自主研发的抗抑郁药物LYBALVI®市场渗透率持续提升，叠加在研的阿尔茨海默症治疗项目取得突破性进展，公司盈利增长曲线有望超预期。
分析师特别指出，阿尔克梅斯独创的剂量精准控制技术平台已建立竞争壁垒，当前估值尚未充分反映其创新管线的商业化潜力。受此评级影响，阿尔克梅斯股价在美东时间7月15日盘前交易时段呈现放量上行态势。
（本文根据公开市场分析师评级信息综合整理）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.